LC - MS/MS를 이용한 혈장과 뇨중에서 Vancomycin의 빠른정량분석

Rapid Quantitative Analysis of Vancomycin in Human Plasma and Urine Using LC-MS/MS

  • Kim, Hohyun (Department of Pharmacokinetics, Seoul Medical Science Institute (SCL)) ;
  • Roh, Hyeongjin (Department of Pharmacokinetics, Biocore. Co. Ltd.) ;
  • Han, Sang-Beom (Department of Pharmacokinetics, Seoul Medical Science Institute (SCL))
  • 투고 : 2002.05.08
  • 발행 : 2002.10.25

초록

본 연구에서는 LC - MS/MS를 이용해 혈장과 뇨중에서 반코마이신을 신속하게 정량분석하는 방법을 개발하였다. 크로마토그래피는 $C_{18}$ XTerra MS 컬럼 ($2.1{\times}30mm$, $3.5{\mu}m$)을 사용하여 분석하였다. 이동상으로는 0.25% 초산이 섞인 10% 아세토니트릴 용액을 사용하였으며, 유속은 $250{\mu}L/min$이다. 반코마이신과 카페인 (내부표준물질)은 multiple reaction monitoring (MRM) 방법을 사용하여 검출하였으며 반코마이신은 precursor ion m/z 725.0 ( $[M+2H]^{2+}$)와 product ion m/z 100.0을 사용하였다. 혈장에서 반코마이신의 검출한계는 1 nM이며 좋은 정확성과 정밀성을 보여주었다. 또한 혈장중에서 반코마이신의 정량범위는 $0.01{\mu}M$ - $100{\mu}M$이다. 혈장과 뇨중에서 반코마이신을 정량하는 이 분석방법은 약물동력학연구 및 관련연구에 성공적으로 적용되었다.

In this study, a new quantitative analytical method has been developed for the rapid determination of vancomycin in human plasma and urine using liquid chromatography/tandem mass spectrometry (LC - MS/MS). Chromatography was carried out on a $C_{18}$ XTerra MS column ($2.1{\times}30mm$) with a particle size of $3.5{\mu}m$. The mobile phase was 0.25% formic acid in 10% acetonitrile and the flow rate was $250{\mu}L/min$. Vancomycin and caffeine (internal standard) were detected by MS/MS using multiple reaction monitoring (MRM). Vancomycin gives a predominant doubly protonated precursor molecule ($[M+2H]^{2+}$) at m/z 725.0 and a corresponding product ion of m/z 100.0. Detection of vancomycin was good, accurate and precise, with a limit of detection of 1 nM in plasma. The calibration curves for vancomycin in human plasma was linear in a concentration range of $0.01{\mu}M$ - $100{\mu}M$ for plasma. This method has been successfully applied to determine the concentration of vancomycin in human plasma and urine from pharmacokinetic study and relative studies.

키워드

참고문헌

  1. J. E. Geraci, Mayo Clin. Proc., 52, 631-634 (1977).
  2. R. E. VanScoy, S. N. Cohen, J. E. Geraci and J. A. Washington, Mayo Clin. Proc., 52, 216-219 (1977).
  3. J. E. Geraci and P. E. Hermans, Mayo Clin. Proc., 58, 88-91 (1983).
  4. P. E. Reynolds, Eur. J. Clin. Microbiol. Infect. Dis., 8, 943-950 (1989).
  5. R. Nagarajan, Glycopeptide Antibiotics, 63, ISBN 0-8247-9193 (1994).
  6. E. M. Tracy and s. DiTaranto, J. Pediatr. Oncol. Nurs., 19(2), 60-61 (2002).
  7. M. T. Suller and d. Lloyd, J. Appl. Microbiol., 92(5), 866-872 (2002).
  8. J. J. McAtee, S. L. Castle, Q. Jin and D. L. Boger, Bioorg. Med. Chem. Lett., 12(9), 1319-1322 (2002).
  9. D. W. Backes, H. I. Aboleneen and J. A. Simpson, J. Pharm. Biomed. Anal., 16, 1281-1287 (1998).
  10. J. Bauchet, E. Pussard and J. J. Garaud, J. Chromatogr., 414, 472-476 (1987).
  11. J. Luksa and A. Marusic, J. Chromatogr. B, 667, 277-281 (1995).
  12. P. Favetta, J. Guitton, N. bleyzac, C. Dufresne and J. Bureau, J. Chromatogr. B, 751, 377-382 (2001).
  13. B. Robredo, K. V. Singh, F. Baquero, B.E. Murray and C. Torres, J. Food Microbiol., 54(3), 197-204 (2000).
  14. R. Lorenz, M. Herrmann, A. M. Kassem, N. Lehn, H. Neuhaus and M. Classen, Endoscopy, 30(8), 708-712 (1998).
  15. A. L. Somerville, D. H. wright and J. C. Rotschafer, Pharmacotherapy, 19(6), 702-707 (1999).
  16. L. M. Perino and B. A. Mueller, Ann Pharmacother., 27(7-8), 892-893 (1993).
  17. D. Farin, G. A. Piva, I. Gozlan and R. Kitzes-Cohen, J. Pharm. Biomed. Anal., 18(3), 367-372 (1998).
  18. L. O. White, H. A. Holt, D. S. Reeves and A. P. MacGowan, J. Antimicrob. Chemother., 39(3), 355-361 (1997).
  19. H. Hosotsubo, J. Chromatogr., 487(2), 421-427 (1989).